Sandra Rojas-Caro

发表

The G0/G1 switch gene 2 is a novel PPAR target gene.

T. Jatkoe, W. Wahli, N. Tan, 2005, The Biochemical journal.

A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency.

G. Enns, B. Burton, J. Kane, 2015, The New England journal of medicine.

Survival in infants treated with sebelipase Alfa for lysosomal acid lipase deficiency: an open-label, multicenter, dose-escalation study

J. Gargus, S. Eckert, A. Brassier, 2017, Orphanet Journal of Rare Diseases.

P1212 : Impact of sebelipase alfa on survival and liver function in infants with raidly progressive lysosomal acid lipase deficiency

J. Gargus, A. Quinn, V. Valayannopoulos, 2015 .

Effect of sebelipase alfa on survival and liver function in infants with rapidly progressive lysosomal acid lipase deficiency

J. Gargus, S. Eckert, A. Brassier, 2015 .

Final results of the phase 1/2, open-label clinical study of intravenous recombinant human N-acetyl-α-d-glucosaminidase (SBC-103) in children with mucopolysaccharidosis IIIB.

G. Parker, M. Pineda, C. Whitley, 2019, Molecular genetics and metabolism.

Safety findings from 3 trials of treatment with sebelipase alfa in children and adults with lysosomal acid lipase deficiency

B. Burton, J. Kane, A. Tylki-Szymańska, 2016 .

Quality-controlled measurement methods for quantification of variations in transcript abundance in whole blood samples from healthy volunteers.

M. Brigell, J. Willey, Charles R Knight, 2007, Clinical chemistry.

SBC-103, a recombinant human alpha-N-acetylglucosaminidase, demonstrates mannose-6-phosphate receptor dependent transport in an in vitro blood-brain barrier model

A. Quinn, A. Rossomando, Sandra Rojas-Caro, 2014 .